Published in Int J Endocrinol on November 26, 2015
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 22.71
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab (2002) 4.34
Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab (2006) 3.50
Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer (2007) 3.36
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance". Cancer Cytopathol (2010) 2.55
The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer (2006) 2.52
Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab (2013) 2.34
Molecular diagnostics and predictors in thyroid cancer. Thyroid (2009) 1.98
Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol (2009) 1.96
Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype--papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol (2007) 1.92
A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983-2000). Eur J Cancer (2007) 1.81
Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid (2006) 1.65
Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg (2003) 1.64
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab (2012) 1.62
Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am (2007) 1.55
Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab (2009) 1.55
The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol (2010) 1.37
The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab (2011) 1.35
A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab (2012) 1.30
Follicular lesions of thyroid: a 5-year fine-needle aspiration experience. Cancer (2000) 1.28
Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf) (2006) 1.20
Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) (2007) 1.20
Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology (2009) 1.15
Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer. Ann Surg Oncol (2011) 1.04
A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Hum Pathol (2005) 1.04
BRAF V600E mutation and papillary thyroid cancer. JAMA (2013) 1.03
RAS mutations in thyroid cancer. Oncologist (2013) 1.00
A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Ann Surg (2014) 0.99
Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid (2013) 0.97
Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer. Mol Med (2013) 0.91
Diagnostic utility of BRAFV600E mutation testing in thyroid nodules in elderly patients. BMC Surg (2013) 0.91
Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery (2013) 0.90
BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol (2010) 0.89
Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer. Thyroid (2014) 0.87
The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Biomed Pharmacother (2014) 0.86
Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population. Int J Clin Exp Pathol (2014) 0.86
Clinical outcome, role of BRAF(V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol (Lausanne) (2012) 0.84
Prediction of thyroid extracapsular extension with cervical lymph node metastases (ECE-LN) by CEUS and BRAF expression in papillary thyroid carcinoma. Tumour Biol (2014) 0.83
Update on the molecular diagnosis and targeted therapy of thyroid cancer. Med Oncol (2014) 0.81
Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience. Cancer Cytopathol (2014) 0.77
Extrathyroidal implantation of thyroid hyperplastic/neoplastic cells after endoscopic thyroid surgery. Chin Med Sci J (2014) 0.77